Literature DB >> 21383744

Cancer genomics: from discovery science to personalized medicine.

Lynda Chin1, Jannik N Andersen, P Andrew Futreal.   

Abstract

Recent advances in genome technologies and the ensuing outpouring of genomic information related to cancer have accelerated the convergence of discovery science and clinical medicine. Successful examples of translating cancer genomics into therapeutics and diagnostics reinforce its potential to make possible personalized cancer medicine. However, the bottlenecks along the path of converting a genome discovery into a tangible clinical endpoint are numerous and formidable. In this Perspective, we emphasize the importance of establishing the biological relevance of a cancer genomic discovery in realizing its clinical potential and discuss some of the major obstacles to moving from the bench to the bedside.

Entities:  

Mesh：

Year:  2011        PMID： 21383744     DOI： 10.1038/nm.2323

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  67 in total

Review 1.  Spleen tyrosine kinases: biology, therapeutic targets and drugs.

Authors:  Mauro Riccaboni; Ivana Bianchi; Paola Petrillo
Journal:  Drug Discov Today       Date:  2010-05-27       Impact factor: 7.851

2.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

3.  Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene.

Authors:  J P McGrath; D J Capon; D H Smith; E Y Chen; P H Seeburg; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1983 Aug 11-17       Impact factor: 49.962

4.  Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia.

Authors:  J L Bos; D Toksoz; C J Marshall; M Verlaan-de Vries; G H Veeneman; A J van der Eb; J H van Boom; J W Janssen; A C Steenvoorden
Journal:  Nature       Date:  1985 Jun 27-Jul 3       Impact factor: 49.962

5.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

6.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

7.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

8.  A mouse model for EML4-ALK-positive lung cancer.

Authors:  Manabu Soda; Shuji Takada; Kengo Takeuchi; Young Lim Choi; Munehiro Enomoto; Toshihide Ueno; Hidenori Haruta; Toru Hamada; Yoshihiro Yamashita; Yuichi Ishikawa; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-08       Impact factor: 11.205

9.  Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.

Authors:  P M Pollock; M G Gartside; L C Dejeza; M A Powell; M A Mallon; H Davies; M Mohammadi; P A Futreal; M R Stratton; J M Trent; P J Goodfellow
Journal:  Oncogene       Date:  2007-05-21       Impact factor: 9.867

10.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.

Authors:  Ana M Mendes-Pereira; Sarah A Martin; Rachel Brough; Afshan McCarthy; Jessica R Taylor; Jung-Sik Kim; Todd Waldman; Christopher J Lord; Alan Ashworth
Journal:  EMBO Mol Med       Date:  2009-09       Impact factor: 12.137
View more
  207 in total

1.  Cancer: Solving an age-old problem.

Authors:  Barbara Dunn
Journal:  Nature       Date:  2012-02-29       Impact factor: 49.962

2.  Translating cancer 'omics' to improved outcomes.

Authors:  Emily A Vucic; Kelsie L Thu; Keith Robison; Leszek A Rybaczyk; Raj Chari; Carlos E Alvarez; Wan L Lam
Journal:  Genome Res       Date:  2012-02       Impact factor: 9.043

Review 3.  A New Era of Low-Dose Radiation Epidemiology.

Authors:  Cari M Kitahara; Martha S Linet; Preetha Rajaraman; Estelle Ntowe; Amy Berrington de González
Journal:  Curr Environ Health Rep       Date:  2015-09

Review 4.  Preclinical mouse cancer models: a maze of opportunities and challenges.

Authors:  Chi-Ping Day; Glenn Merlino; Terry Van Dyke
Journal:  Cell       Date:  2015-09-24       Impact factor: 41.582

5.  Making connections: using networks to stratify human tumors.

Authors:  Benjamin J Raphael
Journal:  Nat Methods       Date:  2013-11       Impact factor: 28.547

6.  Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study.

Authors:  Apostolia-Maria Tsimberidou; David S Hong; Yang Ye; Carrie Cartwright; Jennifer J Wheler; Gerald S Falchook; Aung Naing; Siqing Fu; Sarina Piha-Paul; Filip Janku; Funda Meric-Bernstam; Patrick Hwu; Bryan Kee; Merrill S Kies; Russell Broaddus; John Mendelsohn; Kenneth R Hess; Razelle Kurzrock
Journal:  JCO Precis Oncol       Date:  2017-09-08

7.  Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer.

Authors:  Emmanuel Rios Velazquez; Chintan Parmar; Ying Liu; Thibaud P Coroller; Gisele Cruz; Olya Stringfield; Zhaoxiang Ye; Mike Makrigiorgos; Fiona Fennessy; Raymond H Mak; Robert Gillies; John Quackenbush; Hugo J W L Aerts
Journal:  Cancer Res       Date:  2017-05-31       Impact factor: 12.701

8.  Architecture of pharmacogenomic associations: structures with functional foundations or castles made of sand?

Authors:  Dylan M Glubb; Federico Innocenti
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

9.  Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Authors:  Ron Bose; Shyam M Kavuri; Adam C Searleman; Wei Shen; Dong Shen; Daniel C Koboldt; John Monsey; Nicholas Goel; Adam B Aronson; Shunqiang Li; Cynthia X Ma; Li Ding; Elaine R Mardis; Matthew J Ellis
Journal:  Cancer Discov       Date:  2012-12-07       Impact factor: 39.397

Review 10.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.